UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

The New England journal of medicine, 2006-02, Vol.354 (6), p.567-578

2006

Volltextzugriff (PDF)

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Investigational new drugs, 2011-10, Vol.29 (5), p.1029-1037

2011

Volltextzugriff (PDF)

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Investigational new drugs, 2020-10, Vol.38 (5), p.1448-1453

2020

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

Cancer, 2010-02, Vol.116 (4), p.1027-1032

2010

Volltextzugriff (PDF)

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

British journal of haematology, 2014-09, Vol.166 (6), p.862-874

2014

Volltextzugriff (PDF)

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Oncogene, 2000-12, Vol.19 (56), p.6680-6686

2000

Volltextzugriff (PDF)

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

JAMA oncology, 2024-09

2024

Volltextzugriff (PDF)

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Cancer, 2010-02, Vol.116 (S4), p.1018-1026

2010

Volltextzugriff (PDF)

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Volltextzugriff (PDF)

Paclitaxel (Taxol)

The New England journal of medicine, 1995-04, Vol.332 (15), p.1004-1014

1995

Volltextzugriff (PDF)

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Investigational new drugs, 2012-08, Vol.30 (4), p.1597-1606

2012

Volltextzugriff (PDF)

Vascular endothelial growth factor receptor‐1 in human cancer

Cancer, 2010-02, Vol.116 (S4), p.1027-1032

2010

Volltextzugriff (PDF)

Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer

Clinical breast cancer, 2003-06, Vol.4 (2), p.126-137

2003

Volltextzugriff (PDF)

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Cancer, 2010-02, Vol.116 (S4), p.1013-1017

2010

Volltextzugriff (PDF)

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Investigational new drugs, 2010-06, Vol.28 (3), p.334-342

2010

Volltextzugriff (PDF)

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

Investigational new drugs, 2011-06, Vol.29 (3), p.481-488

2011

Volltextzugriff (PDF)

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

Investigational new drugs, 2011-02, Vol.29 (1), p.167-174

2011

Volltextzugriff (PDF)

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

Investigational new drugs, 2007-08, Vol.25 (4), p.359-367

2007

Volltextzugriff (PDF)

The Current Status of Camptothecin Analogues as Antitumor Agents

JNCI : Journal of the National Cancer Institute, 1993-02, Vol.85 (4), p.271-291

1993

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies

Investigational new drugs, 2012-02, Vol.30 (1), p.316-326

2012

Volltextzugriff (PDF)

Therapeutics targeting signal transduction for patients with colorectal carcinoma

British medical bulletin, 2002-01, Vol.64 (1), p.227-254

2002

Volltextzugriff (PDF)

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies

Annals of neurology, 1994-03, Vol.35 (3), p.304-311

1994

Volltextzugriff (PDF)

Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.2589-2589

2017

Volltextzugriff (PDF)

Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma

Investigational new drugs, 2001-02, Vol.19 (1), p.69-76

2001

Volltextzugriff (PDF)

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs

Clinical lung cancer, 2004-12, Vol.6 Suppl 1, p.S35-S42

2004

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Aktive Filter

KollektionIngenta

KollektionWK Lippincott Williams & Wilkins–Connect here FIRST to enable access

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(78)
Mit Volltextzugriff
(75)

Publikationsform

Artikel
(78)

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Thema

Humans
(48)
Life Sciences & Biomedicine
(43)
Science & Technology
(43)
Oncology
(34)
Biological And Medical Sciences
(29)
Medical Sciences
(29)
Female
(26)
Antineoplastic Agents
(24)
Male
(24)
Pharmacology. Drug Treatments
(23)
Aged
(22)
Middle Aged
(22)
Adult
(21)
Antineoplastic Agents - Therapeutic Use
(21)
Chemotherapy
(19)
Tumors
(18)
Pharmacology & Pharmacy
(16)
Cancer Therapies
(14)
Toxicity
(13)
Antineoplastic Agents - Adverse Effects
(12)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

Phase 1 study of the protein deubiquitinase inhibitor VLX1570 in patients with relapsed and/or refractory multiple myeloma

Vascular Endothelial Growth Factor Receptor-1 in Human Cancer: Concise Review and Rationale for Development of IMC-18F1 (Human Antibody Targeting Vascular Endothelial Growth Factor Receptor-1)

SL‐401 and SL‐501, targeted therapeutics directed at the interleukin‐3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

Chimeric Antigen Receptor T Cells Targeting CD19 and GCC in Metastatic Colorectal Cancer: A Nonrandomized Clinical Trial

Rationale for the development of IMC‐3G3, a fully human immunoglobulin G subclass 1 monoclonal antibody targeting the platelet‐derived growth factor receptor α

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

Paclitaxel (Taxol)

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

Vascular endothelial growth factor receptor‐1 in human cancer

Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer

Targeting FMS‐related tyrosine kinase receptor 3 with the human immunoglobulin G1 monoclonal antibody IMC‐EB10

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer

Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

A phase II and pharmacological study of the matrix metalloproteinase inhibitor (MMPI) COL-3 in patients with advanced soft tissue sarcomas

The Current Status of Camptothecin Analogues as Antitumor Agents

Phase I and pharmacokinetic study of 3′-C-ethynylcytidine (TAS-106), an inhibitor of RNA polymerase I, II and III,in patients with advanced solid malignancies

Therapeutics targeting signal transduction for patients with colorectal carcinoma

Peripheral neuropathy from taxol and cisplatin combination chemotherapy: Clinical and electrophysiological studies

Phase 1 study of the bone-targeting cytotoxic conjugate, etidronate-cytosine arabinoside (MBC-11), in cancer patients with bone metastases

Phase II study of 4-Ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma

Effect of epidermal growth factor receptor mutations on the response to epidermal growth factor receptor tyrosine kinase inhibitors: target-based populations for target-based drugs

Aktive Filter

Suchergebnisse filtern